Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Freitag

Showing results (161-170 of 164) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 164 results.
Headache|April 21, 2007
Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS)Frederick G Freitag, Gary Finlayson, Alan M Rapoport, et al.
Headache|February 16, 2007
Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trialStephen D Silberstein, Richard B Lipton, David W Dodick, et al.
Headache|December 7, 2007
The impact of topiramate on health-related quality of life indicators in chronic migraineDavid W Dodick, Stephen Silberstein, Joel Saper, et al.
Cephalalgia : an International Journal of Headache|June 16, 2004
LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraineC N Sang, N M Ramadan, R G Wallihan, et al.
Pageof 17

Showing results (161-170 of 164) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 164 results.
Headache|April 21, 2007
Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS)Frederick G Freitag, Gary Finlayson, Alan M Rapoport, et al.
Headache|February 16, 2007
Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trialStephen D Silberstein, Richard B Lipton, David W Dodick, et al.
Headache|December 7, 2007
The impact of topiramate on health-related quality of life indicators in chronic migraineDavid W Dodick, Stephen Silberstein, Joel Saper, et al.
Cephalalgia : an International Journal of Headache|June 16, 2004
LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraineC N Sang, N M Ramadan, R G Wallihan, et al.
Pageof 17